Bristol-Myers Squibb Company (BMY)vsPDD Holdings Inc. (PDD)
BMY
Bristol-Myers Squibb Company
$58.94
+2.70%
HEALTHCARE · Cap: $120.03B
PDD
PDD Holdings Inc.
$102.61
+4.61%
CONSUMER CYCLICAL · Cap: $139.25B
Smart Verdict
WallStSmart Research — data-driven comparison
PDD Holdings Inc. generates 768% more annual revenue ($418.54B vs $48.19B). PDD leads profitability with a 24.4% profit margin vs 14.6%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).
BMY
Buy64
out of 100
Grade: C+
PDD
Strong Buy77
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.0%
Fair Value
$161.93
Current Price
$58.94
$102.99 discount
Margin of Safety
+67.8%
Fair Value
$332.33
Current Price
$102.61
$229.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 31 in profit
Conservative balance sheet, low leverage
Generating 45.7B in free cash flow
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
1.3% revenue growth
Distress zone — elevated risk
Elevated debt levels
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.
Bull Case : PDD
The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.
Bear Case : BMY
The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : PDD
No major red flags identified for PDD, but monitor valuation.
Key Dynamics to Monitor
BMY profiles as a value stock while PDD is a mature play — different risk/reward profiles.
BMY carries more volatility with a beta of 0.27 — expect wider price swings.
PDD is growing revenue faster at 9.0% — sustainability is the question.
PDD generates stronger free cash flow (45.7B), providing more financial flexibility.
Bottom Line
PDD scores higher overall (77/100 vs 64/100), backed by strong 24.4% margins. BMY offers better value entry with a 63.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →PDD Holdings Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · China
Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?